Situation: A leading international life sciences company had to explain in court why its settlement of patent litigation with a potential generic entrant was driven by legitimate business considerations.
CRA contribution: CRA assembled a team with expertise in the pharmaceuticals industry, antitrust analysis, and game theory. Our economic analysis of the settlement accounted for the business risks facing the parties as well as the potential for a delay in generic entry.
Result: CRA’s expert analysis supported the defendant’s pre-trial motions, which were successful in having the case dismissed.
CRA Sessions | Readily ascertainable? AI’s role in redefining trade secrets
Intellectual property expert and host David Duski (CRA) joins Brian Nolan (Mayer Brown), to explore the evolving intersection of AI and trade secret law.